Status:
COMPLETED
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
Lead Sponsor:
Alexandria University
Conditions:
Female Infertility
Eligibility:
FEMALE
20-38 years
Phase:
PHASE4
Brief Summary
Hormonal milieu during implantation is crucial to embryo-endometrium interaction and to the viability of the conceptus. Alterations in the peri-implantation environment are considered to impair perina...
Eligibility Criteria
Inclusion
- Patient age ≤ 38 years.
- BMI ≤ 30.
- Basal follicle stimulating hormone (FSH) level ≤ 10 IU/L.
- Anti-Müllerian hormone (AMH): ≤ 5 ng/ml.
Exclusion
- Endometriosis.
- Polycystic ovarian syndrome (PCOS).
- Uterine pathology or anomaly.
- Evidence of hydrosalpinx by hysterosalpingography or ultrasound.
- Comorbidities: Diabetes mellitus, hypertension, immune diseases.
Key Trial Info
Start Date :
March 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 18 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05286554
Start Date
March 17 2022
End Date
January 18 2024
Last Update
January 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria University
Alexandria, Alexandria Governorate, Egypt, 21526